If we have to wait for another two P3s for heart and back pain in order for both products to be commercialised in the US that wound be VERY disappointing.
I must say I do find the delay on the readouts for both these trials very frustrating and slightly worrying. The company was saying ight up until about May or June that it would be mid year. Does it really take up to a year to analyse data for a trial after the final follow up has completed? Smells a bit fishy to me.
Saying covid is responsible for the delays is not good enough. Something more specific is justified.
Regenerative Medicine and Cell Therapies Virtual Event, page-45
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |